Article
Nanoscience & Nanotechnology
Iris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, Juan F. F. Blandez, Vicente Candela-Noguera, Ana Lluch, Begona Bermejo, Felix Sancenon, Juan Miguel Cejalvo, Ramoin Martinez-Manez, Pilar Eroles
Summary: Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this study, a nanodevice using mesoporous silica nanoparticles for miR-200c-3p delivery was designed and validated. The nanodevice demonstrated biocompatibility, escape ability from endosomes/lysosomes, and inhibition of tumor progression, invasion, migration, and proliferation in vitro. In vivo experiments confirmed tumor targeting, effective miR-200c-3p delivery, therapeutic efficacy with reduced tumor size and lung metastasis, and no signs of toxicity. Overall, miR-200c-3p-loaded nanoparticles present a potential strategy for breast cancer therapy and safe tumor-targeted delivery of microRNAs.
ACS APPLIED MATERIALS & INTERFACES
(2023)
Article
Chemistry, Physical
Wei Wang, Fengmin Zhong, Dun Wang, Yuqi Zhao, Dongdong Peng, Shuang Li, Qian Ning, Shengsong Tang, Cui-Yun Yu, Hua Wei
Summary: The construction of dual gatekeepers-functionalized mesoporous organic silica nanoparticles with both physical and chemical mechanisms provides a solution for the extracellular stability and intracellular therapeutic efficiency. This study demonstrates the successful use of diselenium-bridged MONs decorated with a dual gatekeeper, azobenzene/polydopamine, for modulated drug delivery properties.
JOURNAL OF COLLOID AND INTERFACE SCIENCE
(2023)
Article
Engineering, Biomedical
Yupeng Shi, Mengyang Zhou, Yong Zhang, Yifei Wang, Jingliang Cheng
Summary: Image-guided stimulus-responsive theranostics have been developed for enhanced tumor cell clearance through identification of malignant lesions and integration of multiple cell-killing mechanisms. In this study, an intelligent dual-responsive nanostructure (HSPMH-DOX) was designed for MRI-guided synergistic chemo-photothermal therapy and chemodynamic therapy. The nanoagent demonstrated both endogenous and external dual responses, allowing triggered drug release and localized overheating under specific tumor microenvironment and external near-infrared light irradiation. The prepared dual-response nanoagent exhibited excellent biocompatibility, targeting ability, and efficiency for MRI-guided combined therapy in vitro and in vivo. The combination of chemo-PTT and CDT achieved effective tumor eradication in animal models within a short period of time. This work holds great promise for future applications in stimulus-responsive synergistic theranostics.
ACTA BIOMATERIALIA
(2023)
Article
Chemistry, Multidisciplinary
Na Peng, Yijing Du, Guang Yu, Chenglan Zhang, Qun Cai, Hu Tang, Yi Liu
Summary: This study explores the combination of polymeric nanoplatforms with reactive oxygen species (ROS) responsiveness and mitochondria targeting for enhanced photodynamic therapy (PDT). The results show that Ce6-loaded BioPEGDMA@RM, which contains TK linkers, exhibits higher cytotoxicity and ROS production compared to nanoparticles without TK linkages. Additionally, Ce6-loaded BioPEGDMA@RM shows stronger in vitro cytotoxicity and immunologic reactions, suggesting its potential for ROS-responsive drug delivery systems in advanced PDT efficiency.
Article
Pharmacology & Pharmacy
Xi Ye, Xin Chen, Ruixi He, Wangyang Meng, Weidong Chen, Fengling Wang, Xiangyun Meng
Summary: This study developed a novel liposome, CUR-DTX-L, to address multidrug resistance and low efficacy in breast cancer treatment. The liposome showed sustained release and better antitumor efficacy compared to free drugs, and promising pharmacokinetic properties, making it a potential drug delivery system for synergistic treatment of breast cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Fatemeh Ahmadi, Arezoo Sodagar-Taleghani, Pedram Ebrahimnejad, Seyyed Pouya Hadipour Moghaddam, Farzam Ebrahimnejad, Kofi Asare-Addo, Ali Nokhodchi
Summary: Cancer, the second leading cause of death worldwide, poses challenges for conventional therapies. Nanomaterials, particularly mesoporous silica nanoparticles (MSNs), have been developed to overcome the limitations of conventional cancer treatments. This review highlights the latest progress in using MSNs for cancer diagnosis and treatment, including stimuli-responsive drug delivery, surface modification for targeting, multifunctional MSNs in drug delivery systems, and their potential as imaging platforms. The physicochemical attributes of MSNs and their impact on cancer therapy, as well as challenges and safety concerns, are discussed.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Article
Medicine, Research & Experimental
Sara N. Musetti, Leaf Huang
Summary: The study found that Tinagl1 gene therapy can slow tumor growth in triple negative breast cancer without toxicity. Additionally, the use of Tinagl1 significantly increases tumor vasculature without increasing permeability or metastasis risk. Furthermore, the increase in vasculature from Tinagl1 therapy reduces the expression of Hif1a, potentially decreasing drug resistance risk.
MOLECULAR PHARMACEUTICS
(2021)
Article
Chemistry, Multidisciplinary
Polina A. Demina, Anatolii A. Abalymov, Denis V. Voronin, Alexandr V. Sadovnikov, Maria V. Lomova
Summary: The study introduces anticancer hybrid mineral highly-magnetic protein-tannin vehicles as tunable and controllable triggers for drug delivery systems. Results show effective encapsulation and storage of drugs in the vehicles, with a higher cytostatic effect on breast cancer cells compared to healthy cells. The core-shell magnetic anticancer structures show potential for long-term preservation of antitumor drugs.
MATERIALS CHEMISTRY FRONTIERS
(2021)
Review
Pharmacology & Pharmacy
Atena Abed, Maryam Derakhshan, Merat Karimi, Matin Shirazinia, Maryam Mahjoubin-Tehran, Mina Homayonfal, Michael R. Hamblin, Seyed Abbas Mirzaei, Hamidreza Soleimanpour, Sadegh Dehghani, Farnaz Farzaneh Dehkordi, Hamed Mirzaei
Summary: Cancer is a major global health issue and the current treatments often have severe side effects and face drug resistance. Platinum nanoparticles (PtNPs) are being researched as a new therapeutic agent for cancer, with their antioxidant properties and ability to target tumors, improving the efficacy and reducing the side effects of treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, Research & Experimental
Xiangjun Chen, Mingyi Hou, Xinzhong Zhang, Haixin Liu, Wenting Li, Wei Hong
Summary: Nanoscale structures have been developed for various functions in cancer therapy, including diagnosis, biomedical visualization, tissue regeneration, and drug delivery. By using biocompatible chitosan oligosaccharides and gold nanorods, a drug delivery system was designed that effectively delivered drugs to tumor sites and selectively targeted cancer cells. The system also had drug release capability and magnetic resonance imaging functionality, showing promising outcomes for tumor diagnosis and treatment.
MOLECULAR PHARMACEUTICS
(2023)
Review
Pharmacology & Pharmacy
Nisar Ul Khaliq, Juyeon Lee, Joohyeon Kim, Yejin Kim, Sohyeon Yu, Jisu Kim, Sangwoo Kim, Daekyung Sung, Hyungjun Kim
Summary: Cancer remains a major global health challenge, and traditional chemotherapy often leads to side effects and drug resistance, necessitating the development of alternative treatments like gene therapy. Mesoporous silica nanoparticles (MSNs) offer numerous advantages as gene delivery carriers, including high loading capacity, controlled drug release, and easy surface functionalization. They are biodegradable and biocompatible, making them promising candidates for drug delivery applications. Recent studies have reviewed the use of MSNs for delivering therapeutic nucleic acids to cancer cells and discussed their potential as a tool for cancer therapy. The major challenges and future interventions of MSNs as gene delivery carriers for cancer therapy are also discussed.
Article
Biotechnology & Applied Microbiology
Yanhong Liu, Meiyan Wang, Wanru Liu, Jili Jing, Hongshuang Ma
Summary: In this study, olaparib and doxorubicin were co-loaded on disulfide bond cross-linked polypeptide nanogels for the treatment of breast cancer in mouse models. The dual-drug-co-loaded nanogels showed the best anti-cancer effect and excellent biological safety, making them a promising approach for anti-cancer treatment.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Review
Chemistry, Physical
Arezoo Sodagar Taleghani, Ali Taghvaie Nakhjiri, Mohammad Javad Khakzad, Seyed Mahdi Rezayat, Pedram Ebrahimnejad, Amir Heydarinasab, Azim Akbarzadeh, Azam Marjani
Summary: In recent decades, significant progress has been made in cancer treatment, but finding more effective therapies is crucial. The application of drug delivery nanovehicles, particularly mesoporous silica nanoparticles (MSNPs), shows promise in reducing side effects. MSNPs possess excellent characteristics that make them suitable for targeted and stimuli responsive drug delivery in cancer treatment.
JOURNAL OF MOLECULAR LIQUIDS
(2021)
Article
Oncology
Sihao Zhu, Ziyuan Li, Dongye Zheng, Yue Yu, Jing Xiang, Xiao Ma, Dongqing Xu, Jiajun Qiu, Ziyu Yang, Zhiyi Wang, Jun Li, Hongfang Sun, Weiqiang Chen, Xiangxi Meng, Yanye Lu, Qiushi Ren
Summary: In this study, a membrane-coated delivery system was developed for the therapeutic and diagnostic use of miRNA in tumors. The system showed low toxicity, high loading efficiency, and superior targeting ability. It inhibited tumor angiogenesis, growth, and migration, making it a promising nanoplatform for colorectal cancer theranostics.
MOLECULAR THERAPY-ONCOLYTICS
(2023)
Review
Pharmacology & Pharmacy
Xiaowei Xie, Tianxiang Yue, Wenting Gu, Weiyi Cheng, Li He, Weiye Ren, Fanzhu Li, Ji-Gang Piao
Summary: This paper discusses the use of surface-functionalized mesoporous silica nanoparticles (MSN) as delivery vehicles for siRNA in cancer therapy. The advantages of using MSNs for siRNA loading and strategies to improve cellular uptake and endosomal escape are highlighted. Attention is also paid to the exciting progress made by combining RNAi with other therapies to improve cancer therapeutic outcomes.
